Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.
Bailón L, Moltó J, Curran A, Cadiñanos J, Carlos Lopez Bernaldo de Quirós J, de Los Santos I, Ambrosioni J, Imaz A, Benet S, Suanzes P, Navarro J, González-García J, Busca C, Pérez-Latorre L, Berenguer J, García-Fraile LJ, Mejía-Abril G, Miró JM, Scévola S, Moreno S, Domingo P, Tian Y, Frankot M, Lim D, Cai Y, Vendrame E, Guo S, Wallin JJ, Geleziunas R, SenGupta D, Alarcón-Soto Y, Leal I, Aranguen A, Garcia-Garcia M, McGowan I, Brander C, Arribas JR, Mothe B; AELIX-003 Study Group.
Bailón L, et al. Among authors: imaz a.
Nat Commun. 2025 Mar 4;16(1):2146. doi: 10.1038/s41467-025-57284-w.
Nat Commun. 2025.
PMID: 40038256
Free PMC article.
Clinical Trial.